Moderna’s stock dropped as much as 25% on Thursday after trial data for its long-awaited melanoma vaccine leaked on social media. Then the full results came out, and they were largely positive.

That is the part that should stop you for a second.

The treatment combines Moderna’s mRNA vaccine technology with Merck’s immunotherapy drug Keytruda. In a Phase 3 trial of more than 1,100 melanoma patients whose tumors had been removed by surgery, the combination cut the risk of recurrence or death by 42% compared with Keytruda alone. It also reduced the risk that the cancer would spread to distant parts of the body, or that a patient would die, by 38%.

Those are not small numbers. For people with high-risk melanoma, “the cancer came back” is the fear that follows you after surgery. A therapy that lowers that risk meaningfully is a real medical result.

Analyst Evan Seigerman described the full findings as “largely positive.”

What actually happened

The trouble began before Moderna and Merck made their official announcement. Partial data from the trial appeared on social media, and investors reacted fast. Moderna shares fell as much as 25% during Thursday trading before recovering some ground later.

By the close, the stock was still down more than 17%. Reuters reported that the sell-off erased roughly $24 billion in market value.

So the market saw a promising cancer treatment and sold it hard. That sounds irrational until you remember what the market had already priced in.

Moderna’s stock had surged in the months before the results. Investors were hoping for another leap forward from a company that became famous for its COVID vaccine. When the detailed Phase 3 numbers arrived, some traders decided the results did not beat the very high expectations already built into the share price. Analysts called it a “sell-the-news” reaction.

In plain English: the treatment may have been good. The stock had been priced for spectacular.

Why the numbers matter

The vaccine, called intismeran autogene, is personalized. It is built using information from a patient’s own tumor, then paired with Keytruda, an immunotherapy that helps the immune system attack cancer cells.

In the trial, about 82% of patients who received the vaccine plus Keytruda were alive without their melanoma returning two years after treatment. Among patients who received Keytruda alone, that figure was 70%.

Put another way, the difference was about 12 percentage points after two years. That is not a cure claim. It is not a promise that every patient will be fine. But it is a meaningful improvement over an already strong existing treatment.

Keytruda alone is a hard act to follow. After two years, 70% of patients receiving it had not relapsed. The vaccine combination pushed that to 82.2%.

The part that got lost

A 42% reduction in recurrence or death sounds impressive until you compare it with earlier results. In a smaller Phase 2 trial, the same combination had shown a 49% reduction in the risk of recurrence or death after longer follow-up.

The new Phase 3 result was still positive. It still met its primary endpoint. But it was lower than the earlier figure, and Wall Street had been hoping for more.

That gap, plus the leak, was enough to send the stock into a dive.

And here is the detour: we have gotten used to treating stock charts like a scoreboard for human progress. They are not. A share price measures expectations, timing, risk, and money. A clinical trial measures whether a treatment helped patients in a study. Those two things can move in opposite directions on the same day.

That is what happened here.

What we still do not know

The companies reported that the trial met its main goals. The full data showed significant reductions in recurrence or death and in distant spread or death.

What remains unclear is how regulators will weigh the results, whether the treatment will win approval, how it will be manufactured at scale, what it will cost, and how it will perform outside the controlled setting of a clinical trial. Those questions do not get answered by a stock chart or a leaked post.

The treatment is still investigational. It has not yet been approved as a standard melanoma therapy based on this announcement alone.

The quiet part

For investors, Thursday was about a 25% drop and billions in lost value. For patients and doctors, the story was different: a late-stage trial showed that a personalized mRNA vaccine, added to an existing immunotherapy, reduced the risk of melanoma coming back or spreading.

I keep thinking about how easily those two stories collided. A medical advance leaked early, got judged by a market built for speed, and briefly looked like bad news because it was not miraculous enough.

Explore: Local News

It should not have to be miraculous to matter.